5350; telephone number: (410) 305–2637; email address: *smith.lisas@epa.gov*.

For information on the draft guidance contact: César E. Cordero, Efficacy Branch (7510M), Antimicrobials Division, Office of Pesticide Programs, Environmental Protection Agency, William Jefferson Clinton East Building, 1200 Pennsylvania Ave. NW, Washington, DC 20460; telephone number: (202) 564–3716; email address: cordero.cesar@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this action apply to me?

This action is directed to the public in general; although this action may be of particular interest to those persons who are or may be required to conduct efficacy testing of chemical substances under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Since other entities may also be interested, the Agency has not attempted to describe all the specific entities that may be affected by this action. If you have any questions regarding the applicability of this action to a particular entity, consult the person listed under FOR FURTHER INFORMATION

- B. What should I consider as I prepare my comments for EPA?
- 1. Submitting CBI. Do not CBI to EPA through https://www.regulations.gov or email. If you wish to include CBI in your comment, please follow the applicable instructions at https:// www.epa.gov/dockets/commenting-epadockets#rules and clearly mark the part or all of the information that you claim to be CBI. In addition to one complete version of the comment that includes information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the public docket. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2.
- 2. Tips for preparing your comments. When preparing and submitting your comments, see the commenting tips at https://www.epa.gov/dockets/commenting-epa-dockets.

II. Background

Legionella pneumophila is a bacterium that is often identified as the causative agent of Legionnaires' Disease, which is a disease acquired by inhaling water droplets contaminated with Legionella bacteria. Legionellae are found naturally in freshwater environments but can become a health

concern when they grow and spread in human-made building water systems like cooling towers. Cooling towers are a potential breeding ground for *L*. pneumophila and subsequent aerosolization of *L. pneumophila* can occur if cooling towers are not properly disinfected and maintained. Following a Legionnaires' disease outbreak in New York City in 2015, New York State began requiring cooling towers to be registered with the state and monitored and treated for L. pneumophila. However, EPA currently does not have guidance providing a framework for those seeking to register antimicrobial products with public health claims to reduce *Legionella* in cooling tower water. EPA received requests to develop a test method and guidance for registration of antimicrobial products intended to reduce L. pneumophila in water used in cooling tower systems. There is significant interest from stakeholders and the public in the availability of antimicrobial products with these claims.

III. Guidance Documents Do Not Contain Binding Requirements

As guidance, these documents are not binding on the Agency or any outside parties, and the Agency may depart from these documents where circumstances warrant and without prior notice. While EPA has made every effort to ensure the accuracy of the discussion in the guidance, the obligations of EPA and the regulated community are determined by statutes, regulations, or other legally binding documents. In the event of a conflict between the discussion in the guidance documents and any statute, regulation, or other legally binding document, the guidance documents will not be controlling.

Authority: 7 U.S.C. 136 et seq.

Dated: September 26, 2023.

Michal Freedhoff,

Assistant Administrator, Office of Chemical Safety and Pollution Prevention.

[FR Doc. 2023-21643 Filed 9-29-23; 8:45 am]

BILLING CODE 6560-50-P

EQUAL EMPLOYMENT OPPORTUNITY COMMISSION

[Agency Docket No: EEOC-2023-0005]

RIN: 3046-ZA02

Proposed Enforcement Guidance on Harassment in the Workplace

AGENCY: Equal Employment Opportunity Commission.

ACTION: Notice of availability and request for comment.

SUMMARY: The Equal Employment Opportunity Commission ("EEOC") is announcing that its proposed "Enforcement Guidance on Harassment in the Workplace" is available for public comment.

DATES: Comments must be received on or before November 1, 2023. Please see the sections below entitled **ADDRESSES** and **SUPPLEMENTARY INFORMATION** for additional information on submitting comments.

ADDRESSES: You may submit comments, identified by docket number EEOC–2023–0005 or Regulatory Information Number (RIN) 3046–ZA02, by any of the following methods—please use only one method:

- Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments.
- Fax: 202–663–4114. Only comments of six or fewer pages will be accepted via FAX transmittal, in order to assure access to the equipment. Receipt of FAX transmittals will not be acknowledged, except that the sender may request confirmation of receipt by calling the Executive Secretariat staff at 202–921–2815 (voice), 1–800–669–6820 (TTY), or 1–844–234–5122 (ASL video phone).
- *Mail:* Raymond Windmiller, Executive Officer, Executive Secretariat, U.S. Equal Employment Opportunity Commission, 131 M Street NE, Washington, DC 20507.
- Hand Delivery/Courier: Raymond Windmiller, Executive Officer, Executive Secretariat, U.S. Equal Employment Opportunity Commission, 131 M Street NE, Washington, DC 20507.

Instructions: The Commission invites comments from all interested parties. All comment submissions must include the agency name and docket number (EEOC-2023-0005) or RIN (3046-ZA02) for this guidance. Comments need be submitted in only one of the abovelisted formats. All comments received will be posted without change to https://www.regulations.gov, including any personal information you provide. However, the EEOC reserves the right to refrain from posting libelous or otherwise inappropriate comments, including those that contain obscene, indecent, or profane language; that contain threats or defamatory statements; that contain hate speech directed at race, color, sex, national origin, age, religion, disability, or genetic information; or that promote or endorse services or products.

Docket: For access to the docket to read background documents or comments received, go to https:// www.regulations.gov and search for "EEOC-2023-0005" or "RIN 3046-ZA02." The received comments also will be available for review at the Commission's library, 131 M Street NE, Suite 4NW08R, Washington, DC 20507, between the hours of 9:30 a.m. and 5:00 p.m., from November 1, 2023 until the Commission publishes the guidance in final form. You must make an appointment with library staff to review the comments in the Commission's library.

FOR FURTHER INFORMATION CONTACT:

Lynn Davenport, Assistant Legal Counsel, *lynn.davenport@eeoc.gov*; Office of Legal Counsel, 202–856–7072 (voice), 1–800–669–6820 (TTY).

SUPPLEMENTARY INFORMATION:

Background

The EEOC is seeking public comments on all aspects of its proposed "Enforcement Guidance on Harassment in the Workplace" (proposed guidance) pursuant to 29 CFR part 1695. The proposed guidance presents a legal analysis of standards for harassment and employer liability applicable to claims of harassment under the equal employment opportunity statutes enforced by the Commission. The Commission posted and requested public input on a proposed guidance on workplace harassment in January 2017, which was not finalized.

The contents of the final guidance document will not have the force and effect of law and are not meant to bind the public in any way. The document is intended only to provide clarity to the public regarding Commission policies and existing requirements under the law. The standards discussed under EEOC-enforced laws will not necessarily apply to allegations of unlawful harassment under other Federal laws or under State or local laws.

For the Commission:

Charlotte A. Burrows,

Chair.

[FR Doc. 2023-21644 Filed 9-29-23; 8:45 am]

BILLING CODE 6570-01-P

FARM CREDIT SYSTEM INSURANCE CORPORATION

Board of Directors Meeting

SUMMARY: Notice of the forthcoming regular meeting of the Board of Directors of the Farm Credit System Insurance Corporation (FCSIC), is hereby given in

accordance with the provisions of the Bylaws of the FCSIC.

DATES: 10 a.m., Wednesday, October 11, 2023

ADDRESSES: You may observe the open portions of this meeting in person at 1501 Farm Credit Drive, McLean, Virginia 22102–5090, or virtually. If you would like to virtually attend, at least 24 hours in advance, visit FCSIC.gov, select "News & Events," then select "Board Meetings." From there, access the linked "Instructions for board meeting visitors" and complete the described registration process.

FOR FURTHER INFORMATION CONTACT: If

you need more information or assistance for accessibility reasons, or have questions, contact Ashley Waldron, Secretary to the Board. Telephone: 703–883–4009. TTY: 703–883–4056.

SUPPLEMENTARY INFORMATION: Parts of this meeting will be open to the public. The rest of the meeting will be closed to the public. The following matters will be considered:

Portions Open to the Public

- Approval of Minutes for July 12, 2023
- Quarterly FCSIC Financial Reports
- Quarterly Report on Insured Obligations
- Quarterly Report on Annual Performance Plan
- Annual Performance Plan
- Budget 2024–2025

Portions Closed to the Public

• Confidential Report on Insurance Risk

Ashley Waldron,

Secretary to the Board.

[FR Doc. 2023-21681 Filed 9-29-23: 8:45 am]

BILLING CODE 6705-01-P

FEDERAL RESERVE SYSTEM

Notice of Proposals To Engage in or To Acquire Companies Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR part 225) to engage de novo, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at https://www.federalreserve.gov/foia/ request.htm. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington DC 20551–0001, not later than October 17, 2023.

- A. Federal Reserve Bank of New York (Ivan J. Hurwitz, Head of Bank Applications) 33 Liberty Street, New York, New York 10045–0001. Comments can also be sent electronically to comments.applications@ny.frb.org:
- 1. The Goldman Sachs Group, Inc., New York, New York; to engage in community development activities pursuant to section 225.28(b)(12) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System. $\,$

Michele Taylor Fennell,

Deputy Associate Secretary of the Board. [FR Doc. 2023–21737 Filed 9–29–23; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Solicitation of Nominations for Appointment to the Advisory Committee on Breast Cancer in Young Women (ACBCYW)

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC) is seeking nominations for membership on the ACBCYW. The ACBCYW consists of 15 experts in fields associated with breast cancer, disease prevention, early detection, diagnosis, public health, social marketing, genetic screening and counseling, treatment, rehabilitation, palliative care, and survivorship in